Diminished expression of S100A2, a putative tumour suppressor, is an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma

Journal of Otolaryngology - Head and Neck Surgery

Volumn 38, Issue 1, 2009, Pages 16-22

  Almadori, Giovanni ^a   Bussu, Francesco ^a   Gall, Jacopo ^a   Rigante, Mario ^a   Lauriola, Libero ^b   Michett, Fabrizio ^c   Maggiano, Nicola ^b   Schafer, Beat W ^e   Heizmann, Claus W ^e   Ranelletti, Franco O ^d   Paludetti, Gaetano ^a  

^a Institute of Otolaryngology

^b Department of Gerontology   (Italy)

^c Institute of Anatomy

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Head and neck; Larynx; Molecular characterization; Prognostic factors; S100A2 Ca2+ binding protein

Indexed keywords

PROTEIN S100A2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LARYNGECTOMY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; NECK TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CHEMOTACTIC FACTORS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LYMPH NODES; NECK; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY DOSAGE; RECURRENCE; S100 PROTEINS;

EID: 64649095929     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology Trends Biochem Sci 1996;21:134-40.
2. Heizmann CW, Cox JA. New perspectives on S100 proteins: a multi-functional Ca2+-, Zn2+- and Cu2+-binding protein family Biometals 1998;11:383-97.
3. Franz C, Durussel l,Cox JA, etal. Binding of Ca2+ and Zn2+ to human nuclear S100A2 and mutant proteins J Biol Chem 1998;273:18826-34.
4. Lee SW, Tomasetto C, Swisshelm K, et al. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment Proc Natl Acad Sci U S A 1992;89:2504-8.
5. Whang-Peng J, Knutsen T, Gazdar A, et al. Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer Genes Chromosomes Cancer 1991 ;3:168-88.
6. Engelkamp D, Schafer BW, Mattei MG, et al. Six S100 genes are clustered on human chromosome 1q21: identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E Proc Natl Acad Sci U S A 1993;90:6547-51.
7. Mischke D, Korge BP, Marenholz I, et al. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21 J Invest Dermatol 1996;106:989-92.
8. Schafer BW, Wicki R, Engelkamp D, et al. Isolation of a Yac clone covering a cluster of 9 S100 genes on human-chromosome-1Q21-rationale for a new nomenclature of the S100 calcium-binding protein family Genomics 1995;25:638-43.
9. Mueller A, Bachi T, Hochli M, et al. Subcellular distribution of S100 proteins in tumor cells and their relocation in response to calcium activation Histochem Cell Biol 1999;111:453-9.
10. Hibi K, Fujitake S, Takase T, et al. Identification of S100A2 as a target of the DeltaNp63 oncogenic pathway Clin Cancer Res 2003;9:4282-5.
11. Sun Y. Identification and characterization of genes responsive to apoptosis: application of DNA chip technology and mRNA differential display Histol Histopathol 2000;15:1271-84.
12. Wicki R, Franz C, Scholl FA, et al. Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation Cell Calcium 1997;22:243-54.
13. llg EC, Schafer BW, Heizmann CW. Expression pattern of S100 calcium-binding proteins in human tumors Int J Cancer 1996;68:325-32.
14. Maelandsmo GM, Florenes VA, Mellingsaeter T, et al. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma Int J Cancer 1997;74:464-9.
15. Xia L, Stoll SW, Liebert M, et al. CaN19 expression in benign and malignant hyperplasias of the skin and oral mucosa: evidence for a role in regenerative differentiation Cancer Res 1997;57:3055-62.
16. Villaret DB, Wang T, Dillon D, et al. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis Laryngoscope 2000;110:374-81.
17. Vellucci VF, Germino FJ, Reiss M. Cloning of putative growth regulatory genes from primary human keratinocytes by subtractive hybridization Gene 1995;166:213-20.
18. Lauriola L, Michetti F, Maggiano N, etal. Prognostic significance of the Ca(2+) binding protein S100A2 in laryngeal squamous-cell carcinoma Int J Cancer 2000;89:345-9.
19. Roland NJ, Rowley H, Scraggs M, et al. MIB-1 and involucrin expression in laryngeal squamous carcinoma: the relationship to host and tumour factors and survival Clin Otolaryngol 1996;21:429-38.
20. Feng G, Xu X, Youssef EM, Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis Cancer Res 2001 ;61 7999-8004.
21. Liu D, Rudland PS, Sibson DR, et al. Expression of calcium-binding protein S100A2 in breast lesions Br J Cancer 2000;83:1473-9.
22. Nagy N, Brenner C, Markadieu N, et al. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration Lab Invest 2001;81:599-612.
23. Maurizi M, Scambia G, Benedetti PP, et al. EGF receptor expression in primary laryngeal cancer: correlation with clinico-pathological features and prognostic significance Int J Cancer 1992;52:862-6.
24. Almadori G, Cadoni G, Galli J, et al. Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse Int J Cancer 1999;84:188-91.
25. Maurizi M, Almadori G, Cadoni G, et al. Cathepsin D concentration in primary laryngeal cancer: correlation with clinico-pathological parameters, EGFR status and prognosis Int J Cancer 1996;69:105-9.
26. Lazaris AC, Lendari I, Kavantzas N, et al. Correlation of tumor markers p53, bcl-2 and cathepsin-D with clinicopathologic features and disease-free survival in laryngeal squamous cell carcinoma Pathol Int 2000;50:717-24.
27. Piantelli M, lacobelli S, Almadori G, et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma J Clin Oncol 2002;20:3850-6.
28. Lee CS, Redshaw A, Boag G. nm23-H1 protein immunoreactivity in laryngeal carcinoma Cancer 1996;77:2246-50.
29. Gunduz M, Ayhan A, Gullu I, et al. nm23 Protein expression in larynx cancer and the relationship with metastasis Eur J Cancer 1997;33:2338-41.
30. Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations Head Neck 2003;25:280-8.
31. Franchi A, Gallo O, Boddi V, Santucci M. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination Clin.Cancer Res 1996;2:1801-8.
32. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer J Clin Oncol 1999;17:3150-9.
33. Spafford MF, Koeppe J, Pan Z, et al. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma Arch Otolaryngol Head NeckSurg 1996;122:627-32.
34. Jin YT, Kayser S, Kemp BL, et al. The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma Cancer 1998;82:2159-65.
35. Shah JP, Karnell LH, Hoffman HT, et al. Patterns of care for cancer of the larynx in the United States Arch Otolaryngol Head NeckSurg 1997;123:475-83.
36. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006 CA Cancer J Clin 2006;56:106-30.
37. Shah JP, Patel KJ. , Philadelphia, PA, USA: Mosby; 2003. Head and neck surgery and oncology. 3rd ed.
38. Licitra L, Bernier J, Grandi C, et al. Cancer of the larynx Crit Rev Oncol Hematol 2003;47:65-80.
39. Franchin G, Minatel E, Gobitti C, et al. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients Cancer 2003;98:765-72.
40. Spector JG, Sessions DG, Haughey BH, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx Laryngoscope 2001 ;111:1079-87.
41. Ferlito A, Bradley PJ, Rinaldo A. What is the treatment of choice for Tl squamous cell carcinoma of the larynx? J Laryngol Otol 2004;118:747-9.
42. Ferlito A, Rinaldo A, Silver CE, et al. Elective and therapeutic selective neck dissection Oral Oncol 2006;42:14-25.
43. Ferlito A, Rinaldo A, Silver CE, et al. Neck dissection: then and now Auris Nasus Larynx 2006;33:365-74.
44. Wei Wl, Ferlito A, Rinaldo A, et al. Management of the NO neck-reference or preference Oral Oncol 2006;42:115-22.
45. Yilmaz T, Hosal AS, Gedikoglu G, Kaya S. Prognostic significance of histopathological parameters in cancer of the larynx Eur Arch Otol Rhinol Laryngol 1999;256:139-44.
46. Zhang X, Hunt JL, Shin DM, Chen ZG. Down-regulation of S100A2 in lymph node metastases of head and neck cancer Head Neck 2007;29:236-43.
47. Ambrosch P, Kron M, Pradier O, Steiner W. Efficacy of selective neck dissection: a review of 503 cases of elective and therapeutic treatment of the neck in squamous cell carcinoma of the upper aerodigestive tract Otolaryngol Head Neck Surg 2001 ;124:180-7.